Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Posted: 8 August 2022 Neuren Pharmaceuticals (ASX: NEU) today announced that its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome (PMS) and Pitt Hopkins syndrome (PTHS) are open for enrolment. The first subjects…
Burnet teams up with Monash and BioCurate to develop novel HIV antivirals
Posted: 4 August 2022 Burnet Institute, in collaboration with Monash Institute of Pharmaceutical Sciences (MIPS) has received Proof of Concept funding from BioCurate to develop next-generation human immunodeficiency virus (HIV) antivirals. The multi-disciplinary research team, led jointly by…
Breakthrough Victoria announces investment in Seer, powering global expansion
Posted: 25 July 2022 Breakthrough Victoria has announced recently its investment in Victorian medical technology group Seer Medical to support its plan to become a global leader in epilepsy home monitoring and management. Seer is globally renowned as…
NHMRC consultation on options to reach gender equity in the Investigator Grant scheme
Posted: 21 June 2022 The NHMRC has released a discussion paper presenting some options to reach gender equity in the Investigator Grant scheme. There will be a series of eight open forums held in Queensland, New South Wales,…
Acadia submits Rett Syndrome New Drug Application to the FDA
Posted: 19 July 2022 Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) is pleased to report that its US partner Acadia Pharmaceuticals (Nasdaq: ACAD) has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for…
ANDHealth extends partnership with Therapeutic Goods Administration to accelerate digital health regulatory adoption and commercialisation
Posted: July 18 2022 ANDHealth, Australia’s leading digital health commercialisation organisation, has announced the extension of its partnership with the Therapeutic Goods Administration (TGA) to support Australia’s fast-growing digital health sector. The extended partnership will see TGA fund…
Advertising of Therapeutic Goods in Australia – Are your advertising campaigns compliant? – Stephens Lawyers & Consultants
Posted: 23 June 2022 Advertising compliance for therapeutic goods in Australia is complex, requiring one to remain up-to-date on a number of different advertising laws which are administered by different regulators. This article provides a timely reminder that as…
First harvest at medicinal cannabis facility near Mildura in Victoria’s north-west
Posted: 16 June 2022 Key points: The first crop has been harvested from a medicinal cannabis facility built in a former fruit juice factory near Mildura Cann Group received approval to cultivate the crop at the $115 million…
Immutep’s TACTI-002 trial meets primary endpoint in lung cancer
Posted: 6 June 2022 Immutep reports positive Overall Response Rate in its Phase II clinical trial in 1st line NSCLC for PD-L1 all-comers TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients…
Committee for Melbourne – Welcome to our new CEO, Mark Melvin!
Posted: 2 June 2022. I would firstly like to say thank you to our members, stakeholders and secretariat for such a warm welcome. It is in an honour and a privilege to lead the Committee for Melbourne into…
Amplia Therapeutics (ASX:ATX) shows efficacy in model of lung fibrosis
Date posted: 2 June 2022 Amplia has released new data showing that in a head-to-head preclinical comparison, using a mouse model of idiopathic pulmonary fibrosis (IPF), AMP945 showed comparable efficacy to the current standard of care. The current…
Avatar Brokers Celebrates 20 Years
Posted: 30 May 2022 Avatar Brokers are proud to announce a significant milestone in the history of our company, with this month marking our 20th anniversary. Founded on May 29, 2002, Avatar Brokers began its operations after establishing…
